Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Hepatitis D
Primary: Number of Participants With Decline of Hepatitis Delta Virus (HDV) RNA Quantitative Measurements of >2 Logs From Baseline at 12 Weeks of Treatment — 1; 1; 1; 0…
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
Phase 2 N=60 GS-7977 With Ribavirin for Hepatitis C (SPARE)
Hepatitis C
Primary: Participants With Adverse Events — 1; 1; 5; 0 partipants
Phase 2 N=26 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Liver Disease · Hepatitis D
Primary: Number of Participants With Decline of Hepatitis D Virus (HDV) RNA Viral Titer of >2 Logs — 18 Participants
Phase 2 N=24 S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Improvement in Viral Kinetics During the First 2 Weeks of Therapy — 14 participants
Phase 2 N=41 Lamivudine and Adefovir to Treat Chronic Hepatitis B
HBV (Hepatitis B Virus) · Hepatitis B · Hepatitis
Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294
Phase 2 N=24 Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml
Phase 2 N=21 Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Hepatitis B
Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…
Phase 2 N=38 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Ebola
Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples
Phase 2 N=13 Pegylated Interferon to Treat Chronic Hepatitis D
Hepatitis D
Primary: Histological Response at 3 Years — 6 participants
Phase 2 N=12 A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
Hepatitis B
Primary: Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) — 25 Percentage of participants
Phase 2 N=35 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Cirrhosis · Chronic Hepatitis C · Hepatitis C
Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression
Phase 4 N=75 A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Percentage of Participants Who Achieved 0.25 Logarithm to the Base 10 (Log10) Hepatitis B Surface Antigen (HBsAg) Reduction From the Baseline at Week 48 — 4; 96…
Phase 2 N=42 SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Hepatitis C
Primary: To Determine the Effects of Sho-saiko-to on Hepatic Injury in Patients With Chronic Hepatitis C Who Are Intolerant or Have a Specific Contraindication to…